Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Negative 94.4%

Neg 94.4% Neu 0% Pos 0%

Evercore ISI Group analyst Daniel Markowitz maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and lowers the price target from $100 to $90.